Carotid With Bivalirudin Angioplasty

Carotid Artery Disease Clinical Trial

— COBRA  

Official title:

Carotid With Bivalirudin Angioplasty

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00812383
• Other study ID #: COBRA
• Status: Completed
• Phase: Phase 2
• Start date: August 2003
• Est. completion date: December 2019

Study information

• Verified date: October 2020
• Source: Medstar Health Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Single center randomized clinical trial, to evaluate the safety and efficacy of carotid artery stenting using the RX ACCULINK™ Carotid Stent System with RX ACCUNET™ Embolic Protection System or PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System using Angiomax (bivalirudin)versus heparin as the anticoagulant for treatment of occlusive carotid artery disease in low and high risk patient cohorts.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 299
• Est. completion date: December 2019
• Est. primary completion date: July 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The patient must be at least 18 years of age.

• The patient must have a significant diameter reduction of the extracranial or intracranial internal or common carotid artery, defined as =50% stenosis for symptomatic patients or =80% stenosis for asymptomatic patients determined by carotid duplex ultrasound scan and/or carotid angiography.

• Female patients with child bearing potential must have a negative pregnancy test.

• The patient and the patient's physician must agree to have the patient return for a 30-day and one-year clinical and ultrasound imaging follow-up evaluations as indicated in the protocol.

• Reference vessel diameter = 3.5 mm - = 9.0 mm diameter.

Exclusion Criteria:

• The patient has had a recent (<4 weeks) disabling stroke or dementia with major neurologic deficit (stroke scales: Barthel <60, NIH >15, or Rankin >3) at pre-procedure neuro exam.

• The patient has had within four weeks of the treatment procedure an intracranial hemorrhage, hemorrhage stroke, major stroke, or any stroke with mass effect demonstrated on MRI or CT.

• The patient has a known allergy to heparin, bivalirudin, aspirin or to anti-platelet agents that prevents taking aspirin plus ticlopidine or aspirin plus clopidogrel.

• The patient has received fractionated or unfractionated heparin within 8 hours prior to the procedure.

• The patient has a history of prior life-threatening radiocontrast reaction that cannot be pre-treated.

• The patient has a history of bleeding diathesis or coagulopathy within 3 months.

• The patient is currently participating in another study protocol that may influence either procedure results or follow-up evaluations.

• Plasma/serum creatinine > 3.0 mg/dl at time of intervention.

• Hemodynamic instability at the time of intervention.

• Previous stent placement in the ipsilateral carotid distribution.

Angiographic Exclusion Criteria

• The patient has an intracranial tumor, or cerebral arterio-venous malformation(s) > 5mm, aneurysms or severe intracranial stenosis distal to target lesion.

• The patient has inaccessible intracranial arterial stenosis greater in severity than the extracranial internal carotid artery lesion.

• There is angiographic evidence of significant intra-luminal thrombus burden with presumed increased risk of plaque fragmentation and consequent distal embolization.

• There is total occlusion of the ipsilateral carotid artery treatment site with TIMI 0 flow characteristics.

• The reference segment diameter (internal carotid artery segment cephalad to the lesion) is less than 3 millimeters by operator visual estimate.

• The patient has peripheral vascular, supra-aortic or internal carotid artery tortuosity precluding use of catheter-based techniques required for successful CSSA

Related Conditions & MeSH terms

• Carotid Artery Disease
• Carotid Artery Diseases

Intervention

Device:
• RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System
Angiomax (bivalirudin) versus standard anticoagulation with heparin during carotid artery stenting with distal protection clinical endpoint evaluation

Locations

Country	Name	City	State
United States	Washington Hospital Center	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Medstar Health Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate clinical success (<50% residual stenosis at all treatment sites without death, myocardial infarction, stroke or major bleed)		30 days
Secondary	To assess for complications including death, myocardial infarction, major or minor stroke, major or minor bleeding, and vascular complications.		In hospital and 30 days
Secondary	To assess stent patency , and occurence of death or recurrent neurological events		12 months